RFL Q1 R&D expenses rose nearly sixfold to USD 7.5 million
I'm PortAI, I can summarize articles.
Rafael Holdings Inc. reported Q1 2026 financial results with revenue of USD 0.2 million and a net loss of USD 9.8 million, or USD 0.19 per share. The net loss increased due to Cyclo Therapeutics' expenses post-acquisition. R&D expenses rose nearly sixfold to USD 7.5 million. General and administrative expenses increased by 13% to USD 2.8 million. Cash and cash equivalents stood at USD 45.5 million as of October 31, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments